Literature DB >> 4025374

Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease.

C M Roifman, H M Lederman, S Lavi, L D Stein, H Levison, E W Gelfand.   

Abstract

Seven patients with hypogammaglobulinemia and chronic sinopulmonary infections were treated with a preparation of intravenous gammaglobulin. In order to maintain levels of serum IgG at greater than 500 to 750 mg/dl four weeks after infusion, 0.6 g/kg was administered every month. Stable serum levels were achieved after three to eight months. After six to 12 months of this regimen, there was significant reduction in acute infections requiring hospitalization, amelioration of clinical and radiographic evidence of chronic maxillary sinusitis, and improvement in pulmonary symptoms and pulmonary function test results. The administration of increased amounts of IgG intravenously is of benefit in patients with chronic sinopulmonary infections.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4025374     DOI: 10.1016/0002-9343(85)90006-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  29 in total

Review 1.  X-linked agammaglobulinemia.

Authors:  M E Conley; J Rohrer; Y Minegishi
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

2.  Efficacy and safety of subcutaneous vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study.

Authors:  Michael Borte; Isabella Quinti; Annarosa Soresina; Eduardo Fernández-Cruz; Bruce Ritchie; Dirk S Schmidt; Christine McCusker
Journal:  J Clin Immunol       Date:  2011-09-20       Impact factor: 8.317

Review 3.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Plasma-derived medicines: access and usage issues.

Authors:  Albert Farrugia; Josephine Cassar
Journal:  Blood Transfus       Date:  2012-12-21       Impact factor: 3.443

5.  Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.

Authors:  J N Moy; A M Scharenberg; M R Stein; D Suez; R L Roberts; R J Levy; M Ballow; M B Fasano; C H Dash; S J Leach
Journal:  Clin Exp Immunol       Date:  2010-12       Impact factor: 4.330

6.  Intravenous immune globulin impairs anti-bacterial defences of a cyclophosphamide-treated host.

Authors:  A S Cross; G Siegel; W R Byrne; M Trautmann; D S Finbloom
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

7.  Carbamazepine-induced agammagloblinaemia clinically mimicking diffuse panbronchiolitis.

Authors:  Chisho Hoshino; Tadashige Hoshi
Journal:  BMJ Case Rep       Date:  2011-02-16

Review 8.  Current diagnosis and management of sinusitis.

Authors:  L R Willett; J L Carson; J W Williams
Journal:  J Gen Intern Med       Date:  1994-01       Impact factor: 5.128

Review 9.  Intravenous immune globulin in primary immunodeficiency.

Authors:  M Haeney
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 10.  Chronic obstructive pulmonary disease: less common causes--an algorithm for the primary care physician.

Authors:  R C St John; J E Gadek; E R Pacht
Journal:  J Gen Intern Med       Date:  1993-10       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.